ABPI names 5 pharmas as code-breachers; Teva wins 180-day marketing exclusivity for Evista generic;

> Lundbeck, Menarini, Bayer, HRA Pharma UK and GlaxoSmithKline ($GSK) have breached the Association of British Pharmaceutical Industries' code of practice. More

> Teva ($TEVA) has received U.S. approval for a generic of Eli Lilly's ($LLY) Evista tablets, winning the first-to-file 180 day market exclusivity. Release

> Physicians Interactive and McKesson ($MCK) are teaming up to provide Coupons on Demand, which grants healthcare providers access to medication cost-savings offers through an Internet platform. Release

> Sanofi ($SNY) is suing Actavis ($ACT) over allegedly infringing patents on its heart drug Multaq. Report | Release

> AstraZeneca ($AZN) has won U.S. approval for a pen-injector version of once-weekly diabetes med Bydureon. News

> Newcastle, U.K.-based remarketing agency, has won a contract with Fertin Pharma, the world's largest medical chewing gum maker. Report

And Finally... Prospects for Gilead's ($GILD) next-generation hepatitis C drug Sovaldi have made CEO John Martin a billionaire. More

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.